



Development of Novel Pharmaceuticals for the Treatment of Parasitic Diseases

Guest Editor:

Dr. Maria João Gouveia

1. Associate Laboratory for Animal and Veterinary Sciences (AL4Animals), Centre for the Study in Animal Science (CECA), University of Porto, Praça do Coronel Pacheco 42, 4050-083 Porto, Portugal

2. Centre for Parasite Biology and Immunology, Department of Infectious Diseases, National Health Institute Dr. Ricardo Jorge, Rua Alexandre Herculano 321, 4000-055 Porto, Portugal

Deadline for manuscript submissions:

closed (20 May 2023)

Message from the Guest Editor

Parasitic infections such as malaria, schistosomiasis, and leishmaniasis, among others, remain a major public health problem causing substantial mortality and morbidity worldwide. Few novel antiparasitic drugs have emerged in recent decades, and the discovery and development of novel antiparasitic drugs are urgently needed. Strategies such as combinations of existing drugs, improvements to known drugs, de novo discovery, and/or the exploration of natural bioactive compounds, among others, should be explored to improve the treatment of parasitic infections and prevent the development of drug resistance.

This Special Issue aims to discuss the strategies for the discovery and development of novel treatments for parasitic diseases. The design and synthesis of novel drugs or drug derivatives and their antiparasitic activities, structure–activity relationships (SARs), the use of bioinformatics tools (or others) for the discovery of potential drugs, and natural compounds as sources of antiparasitic drugs will be addressed here. Colleagues are invited to submit original research papers, communications, or review articles to this Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma